Abstract
This cross-sectional study assesses the prevalence of congenital cytomegalovirus infection among newborns screened in Minnesota before and during the COVID-19 pandemic.
| Original language | English (US) |
|---|---|
| Pages (from-to) | E2230020 |
| Journal | JAMA Network Open |
| Volume | 5 |
| Issue number | 9 |
| DOIs | |
| State | Published - Sep 2 2022 |
Bibliographical note
Funding Information:Funding/Support: This work was supported by the CDC, the National Vaccine Program Office, the Minnesota Department of Health Newborn Screening Program, and cooperative agreement number 6U19DD001218 from the DRDC.
Funding Information:
Conflict of Interest Disclosures: Dr Schleiss reported receiving grants from the US Centers for Disease Control and Prevention (CDC), the National Institutes of Health, and the University of South Carolina Disability Research and Dissemination Center (DRDC) during the conduct of the study; and receiving personal fees from Moderna, Sanofi, GlaxoSmithKline, and Merck outside the submitted work. Ms Rosendahl and Mr McCann reported receiving grants from the CDC during the conduct of the study. No other disclosures were reported.
Keywords
- COVID-19/epidemiology
- Cytomegalovirus
- Cytomegalovirus Infections/congenital
- Humans
- Infant, Newborn
- Minnesota/epidemiology
- Pandemics
- Prevalence
PubMed: MeSH publication types
- Journal Article
- Research Support, Non-U.S. Gov't
- Research Support, U.S. Gov't, P.H.S.
